{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009599","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.975102+00:00","generated_at":"2026-06-17T09:52:23.959155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Imunon reports 2022 net loss of $35.9M ($5.03/share); cash $38.9M funds into 2025","bullets":["Net loss $35.9M vs $20.8M in 2021; operating expenses up 18% to $25.4M.","Non-cash impairment charge of $13.4M on IPR&D asset; $4.5M interest from preferred stock redemption.","Cash $38.9M at year-end; expects to fund operations into 2025.","OVATION 2 study fully enrolled; Phase 1/2 with bevacizumab opened.","PLACCINE NHP data shows comparable protection to mRNA; stability >9 months at 4°C."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009599","json":"https://secwatch.observer/filing/0001493152-23-009599.json","markdown":"https://secwatch.observer/filing/0001493152-23-009599.md","text":"https://secwatch.observer/filing/0001493152-23-009599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:52:23.959155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"204733deaa712c23a8429b9c187de13b3edd6507","claim":"Imunon, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}